Category: peptide
Aliases: Adlyxin, Lyxumia, AVE0010
Exenatide backbone with a 6-lysine C-terminal extension (and Pro replacement at position 38). Short plasma t½ (~3 h) produces predominantly prandial GLP-1R exposure → strong postprandial glycaemic effect mostly through slowed gastric emptying. Less sustained basal effect than weekly GLP-1 agonists; ELIXA trial was CV-neutral.
SC: 3h